CYT006-AngQb fails to reduce blood pressure in phase IIa study

A double-blind, placebo-controlled, phase IIa study has failed to demonstrate that Cytos Biotechnology’s hypertension vaccine, CYT006-AngQb, is effective in reducing blood pressure. An earlier phase IIa trial with the candidate vaccine had demonstrated clinically relevant and statistically significant blood pressure reductions, and as such the company are examining the new data in detail to try to explain and understand the negative result.

Process development activities and preparations for the previously planned phase IIb study with CYT006-AngQb are being temporarily suspended until the results of a third phase IIa study are available later this year.